Skip to main content

Table 1 Karyotypes, demographics and baseline characteristics

From: Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial

 

Treatment group

(N = 28)

Comparator

(N = 30)

p-value

Karyotype

N (%)

 

Simple X monosomy (45, X)

3 (10.71)

1 (3.33)

0.345 b

Structural abnormalities of the X chromosome (e.g. 46, X, i [Xq], 46, X, Xq or Xp [short or long arm deletions])

6 (21.43)

5 (16.67)

0.644 a

Mosaic Karyotypes

19 (67.86)

24 (80.00)

0.291 a

a. 45, X/46, XX

3 (10.71)

7 (23.33)

0.301 b

b. 45, X/46, XY or 46, XY Yvar/Ydel

2 (7.14)

2 (6.67)

1.000 b

c. 45, X/46, X, i (Xq) or other structural chromosome abnormality

14 (50.00)

15 (50.00)

1.000 a

Baseline characteristic

Mean ± SD

 

Chronological age (year)

6.84 ± 2.62

7.06 ± 2.96

0.883 d

Bone Age (year)

6.03 ± 2.93

5.96 ± 2.63

0.919 d

Height (cm)

106.72 ± 13.49

106.93 ± 14.91

0.955 c

Height SDS

−2.36 ± 0.64

−2.44 ± 0.58

0.450 d

Body Weight (kg)

20.64 ± 8.56

20.88 ± 7.31

0.686 d

BMI (kg/m2)

17.35 ± 3.16

17.64 ± 2.46

0.339 d

TSH (uIU/ml)

3.20 ± 1.64

3.01 ± 1.52

0.619 d

fT4 (ng/dl)

1.40 ± 0.26

1.37 ± 0.20

0.889 d

IGF-1 (ng/ml)

146.57 ± 52.20

143.15 ± 62.96

0.981 d

IGFBP-3 (ug/ml)

3.95 ± 0.98

3.56 ± 0.68

0.083 c

  1. SD Standard Deviation, SDS Standard Deviation Score, BMI Body Mass Index, TSH Thyroid Stimulating Hormone, fT4 Free Thyroxine, IGF-1 Insulin-like Growth Factor-1, IGFBP-3 Insulin-like Growth Factor Binding Protein-3
  2. aChi-square test between treatment groups; b Fisher’s exact test between treatment groups
  3. cTwo sample t-test between treatment groups; d Wilcoxon rank sum test between treatment groups